Kaken Pharmaceutical has secured the rights to develop and commercialize navenibart, an investigational treatment for hereditary angioedema…
Articles by Marisa Wexler, MS
People with hereditary angioedema (HAE) types 1 and 2 had fewer swelling attacks and reported improvements in quality of…
In the years following treatment with the gene-editing therapy lonvoguran ziclumeran, or lonvo-z — also known as NTLA-2002 —…
The use of Orladeyo (berotralstat) — widely approved as a preventive treatment for hereditary angioedema (HAE) — can help…
Treatment with the daily oral therapy Orladeyo (berotralstat) can effectively reduce swelling attack rates in people with hereditary…
To mark Hereditary Angioedema (HAE) Awareness Day this year, the advocacy group HAE International is smiling: The theme…
Biocryst Pharmaceuticals has submitted an application asking the U.S. Food and Drug Administration (FDA) to extend the approval of…
More than 90% of people with hereditary angioedema (HAE) are interested in trying new prophylactic (preventive) treatments, according to…
A simple diagnostic score may help distinguish between two types of angioedema — mast cell-mediated angioedema and drug-induced nonallergic…
Short-term preventive treatment before dental procedures may not be necessary for people with hereditary angioedema (HAE) who are already…